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Abstract: Unspecific gastrointestinal symptoms associated with milk consumption are common.
In addition to lactose, also other components of milk may be involved. We studied whether the partial
hydrolysation of milk proteins would affect gastrointestinal symptoms in subjects with functional
gastrointestinal disorders. In a randomised, placebo-controlled crossover intervention, subjects
(n = 41) were given ordinary or hydrolysed high-protein, lactose-free milkshakes (500 mL, 50 g
protein) to be consumed daily for ten days. After a washout period of ten days, the other product was
consumed for another ten days. Gastrointestinal symptoms were recorded daily during the study
periods, and a validated irritable bowel syndrome-symptom severity scale (IBS-SSS) questionnaire
was completed at the beginning of the study and at the end of both study periods. Blood and urine
samples were analysed for markers of inflammation, intestinal permeability and immune activation.
Both the IBS-SSS score (p = 0.001) and total symptom score reported daily (p = 0.002) were significantly
reduced when participants consumed the hydrolysed product. Less bloating was reported during
both study periods when compared with the baseline (p < 0.01 for both groups). Flatulence (p = 0.01)
and heartburn (p = 0.03) decreased when consuming the hydrolysed product but not when drinking
the control product. No significant differences in the levels of inflammatory markers (tumor necrosis
factor alpha, TNF-α and interleukin 6, IL-6), intestinal permeability (fatty acid binding protein 2,
FABP2) or immune activation (1-methylhistamine) were detected between the treatment periods.
The results suggest that the partial hydrolysation of milk proteins (mainly casein) reduces subjective
symptoms to some extent in subjects with functional gastrointestinal disorders. The mechanism
remains to be resolved.
Keywords: IBS; bloating; functional gastrointestinal disorder; milk; casein; hydrolysation; inflammation
1. Introduction
Functional gastrointestinal disorders (FGDs) are common and often difficult-to-treat ailments [1].
FGDs include both disorders of the lower gastrointestinal tract (GI), such as irritable bowel syndrome
(IBS), and disorders of the upper GI tract, such as functional dyspepsia [2]. In addition to IBS
and dyspepsia, other rather common FGDs include functional bloating, functional constipation and
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functional diarrhoea [2]. Rome IV criteria are used in the differential diagnosis of these and other of
FGDs in clinical trials [2], but they have been less often used in clinical practice.
The treatment of FGDs remains challenging; the efficacy of different drug treatments is often
suboptimal, and adverse effects of many previously marketed drugs have led to market withdrawals [1].
People with FGDs commonly report intolerances to particular food items, such as milk, wheat, onions,
garlic, chili, beans and coffee [3,4]. During the last decade, a low FODMAP (fermentable oligo-, di-,
monosaccharides and polyols) diet has attracted attention and gained acceptance as a dietary means
of treating IBS patients with food intolerance, but it is rarely the ultimate solution [5]; many patients
experience residual symptoms, and not all individuals respond to a low FODMAP diet [5].
Milk and other lactose-containing dairy products may cause functional gastrointestinal symptoms
among people with hypolactasia. It is of interest that 40% of 1900 Finnish subjects with unspecific GI
symptoms visiting an outpatient clinic reported that their GI symptoms were milk-related [6]. However,
the prevalence of hypolactasia in the Finnish population is only around 17% [7]. Therefore, there may
well be additional factors in milk other than lactose that play a role in triggering GI symptoms. The role of
milk proteins in functional disorders has been a less extensively investigated subject. Some preliminary
interventions in diverse patient groups have shown that the milk protein, casein or milk, per se,
with intact proteins might induce gastrointestinal symptoms in some individuals [8–10]. Therefore,
the hydrolysis of milk proteins, in addition to lactose, might be one way to improve the tolerability of
dairy products. Indeed, the first randomised study scrutinising the effect of casein-hydrolysed milk
revealed an enhanced tolerability to milk with hydrolysed β-casein when compared to milk with intact
protein; a difference between the milk products was found in flatulence, rumbling symptoms and the
overall symptoms score favouring β-casein hydrolysed milk [11]. These findings underline the need
for further studies in order to understand the specific role of milk proteins in the treatment of FGDs.
We investigated the hypothesis that gastrointestinal symptoms in patients with FGDs could be reduced
by hydrolysation of β-casein into smaller peptides.
2. Materials and Methods
2.1. Subjects and Study Design
Subjects were recruited via advertisements in Facebook and the internet (www.pronutritionis.net
and www.tervevatsa.fi). The main inclusion criteria were IBS, functional dyspepsia, functional
diarrhoea or functional bloating, according to Rome IV criteria. Further inclusion criteria included
the ability to consume 500 mL lactose-free milk products daily during the intervention and ages
between 18 and 65 years. Subjects were excluded if they had a diagnosis of inflammatory bowel
disease, milk allergy or cancer. In addition, pregnant and lactating women, alcoholics or subjects
taking medications potentially influencing their gastrointestinal functions and subjects participating in
any other clinical trials were not eligible.
A total of 41 subjects, 33 women and 8 men, were recruited. The subjects had been given a diagnosis
of IBS (n = 23), functional dyspepsia (n = 3), functional diarrhoea (n = 6) or functional bloating
(n = 9). Prescreening of candidates was done in a telephone interview. Subjects meeting preliminary
inclusion criteria were invited to a screening study visit, where their health status, possible medications
and dietary restrictions were evaluated. Before entering the study, all subjects provided written
informed consent.
Baseline characteristics of the subjects are presented in Table 1.
The study was a randomised, placebo-controlled, crossover intervention of two groups with
ten-day treatment periods, separated by a washout period of ten days (Figure 1). Subjects were
randomised to the two groups in blocks of four. A person who was not involved with enrolling
the participants or assigning them to the interventions generated the randomisation list. Both the
investigators and the subjects were blinded to the randomisation.
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The subjects were instructed to maintain their habitual diets and the usual level of physical activity
throughout the study. Illnesses, medications or other deviations from normal were recorded daily in
their electronic study diaries. The intake of foods containing dairy proteins was limited during the
ten-day study periods, and the subjects were given a list of such food products. The subjects kept food
records for three days at the end of both treatment periods, and macronutrient and fibre intakes were
calculated for both periods.
Table 1. Baseline characteristics of the subjects (mean ± SD). BMI: body mass index. IBS: irritable
bowel syndrome.
All n = 41 Women n = 33 Men n = 8
Age, years 44.0 ± 10.8 44.9 ± 10.9 40.6 ± 10.2
Height, cm 170.0 ± 10.8 166.8 ± 5.8 182.3 ± 8.3
Weight, kg 75.8 ± 16.2 72.2 ± 15.2 90.2 ± 11.8
BMI, kg/m2 26.2 ± 4.9 26.0 ± 5.3 27.1 ± 2.9
Diagnosis
IBS 23 17 6
Functional dyspepsia 3 3 0
Functional diarrhoea 6 5 1
Functional bloating 9 8 1
The study was approved by the Ethics Committee of the Hospital District of Helsinki and
Uusimaa (HUS/576/2019). The study was registered at ISRCTN registry (https://www.isrctn.com) with
identification number ISRCTN74158117.
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2.2. Study Products and Diet
Chocolate-flavoured, lactose-free, high-protein milkshakes were produced by Valio Ltd, Helsinki,
Finland. The control milkshake was a commercially available product, whereas the hydrolysed product
was prepared specially for this study.
The lactose-free milkshake was produced from ultra-filtered milk concentrate. During ultrafiltration,
a part of the lactose was removed, and proteins were concentrated. After ultrafiltration, the residual
lactose and part of the proteins were hydrolysed by enzymatic hydrolysis. The lactose content of the
milkshakes was <0.01%. Protein hydrolysis was undertaken according to patent EP 2632277B1 [12].
The protein content of the milkshakes was 10%. The hydrolysis of the proteins was controlled such
that the degree of hydrolysis was 6.3 mg free tyrosine/g protein in the test milkshake, as analysed
according to the modified method of Matsubara et al. [13]. The samples were boiled for 4 min at
100 ◦C and centrifuged prior to analysis. Soluble tyrosine was determined from the supernatant after
centrifugation (3000 rcf, 15 min). According to the results of the reversed-phase high-performance
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liquid chromatography method [14], the concentration of β-casein was reduced by 75%, as compared
to the concentration in the control milkshake.
According to sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), whey proteins
were not hydrolysed significantly [15] (Figure 2). SDS-PAGE analyses were carried out using
ready-made 12% Tris-glycine extended polyacrylamide gels (Bio-Rad, Hercules, CA, USA). The amount
of protein added to each sample well was 10 µg. Protein bands were stained with Coomassie Brilliant
Blue R-250 (Bio-Rad, Watford, UK) and compared with molecular weight markers Precision Plus
Protein All Blue Standards (Bio-Rad Laboratories, Hercules, CA, USA).
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Major milk proteins are identified.
During the ten-day study periods, each day, the subjects consumed two bottles of the products
(i.e., 250 mL twice daily), which provided 50 g of milk protein and about 300 kJ of energy. The nutritional
composition of the study products is shown in Table 2. Products were packed in similar unlabelled
cartons and were differentiated with a code on the cap. Subjects were allowed to decide at what time
of the day they consumed the products. The time of day and amount consumed were recorded in
an electronic study diary.
Table 2. Nutritional composition of milkshakes (per 100g of product).
Control Hydrolysed
Energy, kJ/kcal 335/80 322/77
Protein, g 10.6 10.3
Fat, g 1.6 1.5
Carbohydrates, g 5.7 5.5
Lactose, g <0.01 <0.01
The dietician instructed the subjects to follow an otherwise dairy-free diet during the ten-day
study p riods. The only dairy products permitted were study milkshakes. Milk, sour milk, kefir,
yogurt, quark, cream, cheese or other dairy products w re to be excluded, but plant-based alternatives,
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such as oat milk and vegan cheese, were allowed; adherence to these restrictions was monitored with
food diaries.
2.3. Gastrointestinal Symptoms
The occurrence of gastrointestinal symptoms—abdominal pain, flatulence, rumbling, bloating,
diarrhoea, constipation, heartburn and rapid feeling of fullness—was recorded in an electronic study
diary, which the subjects completed for three days before the first study period (baseline, subjects’
habitual diet) and daily during both ten-day study periods. The severity of the subjective symptoms
was evaluated on a scale from 1 (no discomfort) to 5 (severe discomfort). The total symptom score was
then calculated by summing scores for all eight individual symptoms (max score 40).
The irritable bowel syndrome-symptom severity scale (IBS-SSS) questionnaire was filled at the
baseline before the beginning of the study and at the end of both study periods. This questionnaire
evaluated the gastrointestinal pain, bowel dysfunction, IBS severity and overall wellbeing, with scores
being based on a visual analogue scale [16].
2.4. Urine Samples
At the beginning of the study and at the end of both study periods, a 12-h (overnight) urine
sample was collected. Urine was collected into a container containing 7 mL 6 N hydrochloric acid as
the preservative. During collection, the container was stored at 4 ◦C, and subjects returned it to the
study centre on the same day that the collection was finished. The volume of the urine was measured,
and after aliquoting, samples were stored at −70 ◦C. Urine was analysed for a marker of immune
activation, 1-methylhistamine. The concentration of 1-methylhistamine was adjusted for the 12-h
urinary creatinine excretion.
2.5. Blood Samples
Fasting blood samples (20 mL) were collected at the beginning of the study and at the end of both
study periods from the antecubital vein. Plasma was separated, and the samples were stored at −70 ◦C.
Plasma was analysed for two markers of inflammation (interleukin -6, IL-6 and tumor necrosis factor
alpha, TNF-α) and one of intestinal permeability (fatty acid binding protein 2, FABP2).
2.6. Laboratory Methods
The proinflammatory cytokines, TNF-α (HSTA00E) and IL-6 (HS600C), and the intestine-derived
FABP2 (DY3078) were measured from the plasma samples using ELISA kits (R&D Systems, Minnesota,
MO, USA). 1-Methylhistamine (DLD Diagnostika GmbH, Hamburg, Germany) and creatinine
(Invitrogen, Thermo Fisher Scientific, Inc., Waltham, MA, USA) were analysed from urine; the values
were calculated as ng 1-methylhistamine per mg of creatinine.
2.7. Statistical Analyses
The sample size calculation was based on presumable changes in the IBS-SSS. Suitable previously
published data were not available to be used in the power calculations. Therefore, we assumed that the
difference between the study products would be at least 50 points on the 500-point IBS-SSS score and
that the standard deviation of that difference would be 100 points. Thus, a sample size of 34 would
have 80% power to detect this 50-point difference when using a paired t-test with a 0.05 two-sided
significance level. The anticipated drop out was 10–20%, and therefore, 40–44 patients were targeted
for this crossover study.
Daily reported gastrointestinal symptoms (abdominal pain, flatulence, rumbling, bloating,
diarrhoea, constipation, heartburn and rapid feeling of fullness); the total daily symptom score
and the IBS-SSS total score were the primary outcome variables. Symptom scores for all individual
symptoms were calculated for the baseline (mean of three days) and for the study periods (mean of ten
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days). A total daily symptom score was calculated for the gastrointestinal symptoms (mean of eight
symptoms). A repeated-measures analysis of variance (ANOVA) for a crossover design was used to
compare individual symptoms, total symptom scores and IBS-SSS scores between the study periods.
Comparisons to baseline were done as post hoc analyses.
Secondary outcome variables included two inflammatory markers (plasma IL-6 and TNF-α),
one marker of intestinal permeability (plasma FABP2) and a marker of immune activation (urinary
1-methylhistamine). The results for the secondary outcomes were compared using repeated measures
analysis of variance (ANOVA) for the crossover design. The distribution of TNF-α was skewed,
and therefore, data was logarithmically transformed before analysis.
Background diets during both study periods were monitored by using three-day food diaries.
Dietary intakes of macronutrients and fibre were calculated by using the Fineli database available at
its internet interface at www.fineli.fi. Paired t-test was used to analyse differences between the study
periods. The statistical analyses were performed using IBM SPSS Statistics for Windows (version 26.0,
IBM Corp, Armonk, NY, USA). A p-value < 0.05 was considered statistically significant.
3. Results
3.1. Compliance
Thirty-seven subjects completed the study. Two subjects dropped out due to personal reasons
and two subjects due to unpleasant gastrointestinal symptoms. The flow chart is depicted in the
Supplementary Materials Figures S1–S3.
Based on study diaries, where the subjects recorded the consumption of study products daily,
compliance with the study products was excellent. On average, 490 mL/day (of 500 mL/day) of the
control product and 480 mL/day (of 500 mL/day) of the hydrolysed product were consumed. The taste
of both products was assessed as good.
3.2. Gastrointestinal Symptoms
The IBS-SSS total symptom score was lower during the hydrolysed period than during the control
period (p = 0.001). The score also decreased significantly from the baseline during the period with
the hydrolysed product (p = 0.001) but not during the period when they drank the control milkshake
(p = 0.68). The total daily symptom score was significantly lower after consuming the hydrolysed
product in comparison with both the control product (p = 0.002) and the baseline symptom score
(p = 0.001, Table 3).
Table 3. Scores of the irritable bowel syndrome-symptom severity scale (IBS-SSS) questionnaire and
daily reported gastrointestinal symptoms (mean ± SD; n = 37).
Baseline Hydrolysed Control p-Value
Hydrolysed versus Control †
IBS-SSS 199 ± 71 163 ± 74 * 205 ± 75 0.001
Symptom score 14.7 ± 3.9 12.5 ± 2.4 * 14.0 ± 3.4 0.002
Abdominal pain 1.89 ± 0.74 1.61 ± 0.56 1.85 ± 0.67 0.09
Bloating 2.46 ± 1.00 2.05 ± 0.70 * 2.17± 0.88 * 0.72
Flatulence 2.49 ± 0.77 2.12 ± 0.61 * 2.32 ± 0.63 0.16
Rumbling 1.68 ± 0.81 1.39 ± 0.48 1.51 ± 0.59 0.25
Diarrhoea 1.85 ± 0.82 1.55 ± 0.64 1.62 ± 0.68 0.89
Constipation 1.45 ± 0.70 1.42 ± 0.54 1.54 ± 0.74 0.74
Heartburn 1.31 ± 0.56 1.09 ± 0.20 * 1.25 ± 0.40 0.01
Rapid feeling of fullness 1.55 ± 0.97 1.40 ± 0.59 1.38 ± 0.70 0.37
† Repeated measures ANOVA for crossover design. * Significant difference from the baseline (p < 0.05).
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Less heartburn was reported during the hydrolysed period (p = 0.01), while no significant
differences in abdominal pain, flatulence, rumbling, bloating, diarrhoea, constipation or feeling of
fullness were seen between the treatment periods (p > 0.05, Table 3). Significantly less bloating
was reported during both study periods when compared with the baseline (p < 0.01 for both
groups). Flatulence (p = 0.01) and heartburn (p = 0.03) decreased during the consumption of the
hydrolysed product when compared to the baseline but not during the period when they drank the
control milkshake.
3.3. Inflammatory Markers, Intestinal Permeability and Immune Activation
Plasma IL-6 concentrations increased during the hydrolysed period (p = 0.02) but did not differ
significantly from the control period (p = 0.36, Table 4). No significant changes were seen in plasma
FABP2 or TNF-α concentrations between either of the treatment periods or as compared to the baseline.
The level of urinary 1-methylhistamine decreased significantly from the baseline during the period
when they drank the hydrolysed milkshake (p = 0.03), but no difference was evident between the study
periods (p = 0.43).
Table 4. Changes in the concentrations of the markers of inflammation, gut permeability and immune
activation during the study (mean ± SD; n = 37). IL-6: interleukin 6. TNF-α: tumor necrosis factor
alpha. FABP2: fatty acid binding protein 2
Baseline Hydrolysed Control p-Value †
Plasma IL-6, pg/mL 1.16 ± 0.94 1.60 ± 1.34 * 1.28 ± 1.23 0.20
Plasma TNF-α,
pg/mL 0.82 ± 0.35 0.84 ± 0.37 0.84 ± 0.38 0.48
Plasma FABP2,
ng/mL 1.29 ± 0.47 1.42 ± 0.68 1.26 ± 0.52 0.13
Histamine ‡ 131 ± 41 111 ± 37 * 117 ± 44 0.43
† Repeated measures ANOVA for the crossover design. * Significant difference from the baseline (p < 0.05).
‡ Analysed as urinary 1-methylhistamine, ng/mg creatinine.
3.4. Dietary Intakes
Dietary intakes during the treatment periods are reported in Table 5. The median intake of
the energy was similar during both treatment periods, being 8404 kJ/day (2008 kcal/day) during
the hydrolysed period and 8786 kJ/day (2100 kcal/day) during the control period. There were no
statistically significant differences in the energy intake between the periods. Furthermore, the intake of
carbohydrates, proteins, fats or fibres did not differ significantly between the two periods.
Table 5. Dietary intakes of macronutrients and fibres during the treatment periods (mean ± SD).
Hydrolysed Control p-Value †
Energy, KJ/day 8404 ± 1753 8786 ± 2352 0.139
Energy, Kcal/day 2008 ± 419 2100 ± 562 0.139
Protein, g/day 121 ± 28 117 ± 30 0.562
Fat, g/day 76 ± 23 79 ± 33 0.442
Carbohydrates, g/day 185 ± 50 198 ± 65 0.111
Fibre, g/day 27 ± 9 27 ± 9 0.872
† Comparison between study periods assessed by a paired t-test.
4. Discussion
Here, we provide further evidence that hydrolysed milk protein might be better tolerated than
nonhydrolysed milk protein by people with functional gastrointestinal disorders. Both symptom sum
scores (IBS-SSS and daily sum score) displayed improvements during the hydrolysed casein lactose-free
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period when compared to the intact milk protein lactose-free period (control). However, the detected
difference in the effects of the products could not be explained by the biochemical measurements
that we had hypothesised might reflect putative physiological imbalances in subjects with FGDs,
i.e., the presence of low-grade inflammation, increased intestinal permeability or immune activation [1].
The magnitude of the effect was 38 points out of the baseline score of 199 on the IBS-SSS scale,
which translates to a 19% reduction of the symptoms; the other symptom assessment score, a 10-day
average of daily symptom recordings, was in-line with the IBS-SSS outcomes, giving further evidence
that it was a true effect. However, these reductions in the symptoms must be interpreted as moderate,
or even modest, because, quite commonly, a reduction of at least 50 points in the IBS-SSS is referred to
as clinically meaningful [17].
Preliminary human data indicates that milk protein may cause symptoms in sensitive or inclined
individuals without lactose intolerance or milk allergy [8–10]. To the best of our knowledge, only one
previous study has evaluated the specific effects of casein-hydrolysed milk products [11]. In that study,
in agreement with our present results, casein-hydrolysed lactose-free milk was better tolerated than
the regular lactose-free milk tested [11]. These findings, together with our current results, suggest
that milk protein, especially casein, may play a role in triggering gastrointestinal symptoms, at least
in some individuals with self-reported milk sensitivities, even in the absence of lactose intolerance.
On the other hand, milk homogenisation, another often-mentioned possible symptom trigger, does not
seem to play a role in milk sensitivity, according to several randomised studies [18–22].
During recent years, the A1 genetic variant of β-casein has been associated with increased
gastrointestinal symptoms, while A2 β-casein has been associated with reduced individual symptoms
in healthy subjects; i.e., some, but not in all, randomised studies indicate that subjects may have
a better tolerance towards A2 β-casein [23,24]. In our enzymatic hydrolysation method, the majority
of β-casein (75%) is hydrolysed, and both A1 and A2 β-casein are similarly affected, whereas whey
proteins remain intact. Thus, it is possible that the reduction either in total β-casein or only in A1
β-casein during hydrolysation could explain the reduction in gastrointestinal symptoms.
Collectively, these data suggest that intact casein in milk, rather than the homogenisation of milk,
might be one possible culprit behind milk-related gastrointestinal symptoms when the role of lactose
is ruled out, and thus, reducing the casein content of milk products might improve their tolerability in
people affected by FGDs.
The key mechanistic features of FGDs include visceral hypersensitivity, dysbiotic changes in the
microbiota, immune activation and increased intestinal permeability [1]. In our study, we did not
find any statistically significant differences in the measures of the surrogate markers (IL-6, TNF-α,
FABP2 and 1-methylhistamine) of these physiological attributes. The IL-6 concentration was elevated
versus the baseline values during the hydrolysed casein period, which was against our hypothesis,
but no change was detected in the concentration of TNF-α. The post hoc qualitative assessment of
the patient diaries showed that two people had a relatively severe colds during the period when they
were consuming the hydrolysed product, which might have theoretically affected their IL-6 values,
where none had a cold during the control period. However, it remains impossible to determine if the
episodes of colds truly skewed our IL-6 results. Another marker of immune activation, the level of
1-methylhistamine, a metabolite of histamine, was reduced in urine during the hydrolysed period
when compared to the baseline but not when compared to the levels measured during the regular milk
protein period. These seemingly contradictory findings open up the possibility that histamine may be
a more sensitive marker of immune activation than classical blood markers of low-grade inflammation
in cases of functional gastrointestinal disorders; naturally, this hypothesis must be tested in future
randomised studies; our data can only act as a starting point for these investigations.
Interestingly, previous systematic reviews have suggested that an over-representation of mast
cells, which secrete histamine in gut epithelia, is the most common and prominent marker of increased
immune activation in IBS [25,26]. Furthermore, in a previous study, a low-FODMAP diet reduced
urine histamine levels by approximately 80% and effectively reduced symptoms when compared to
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a high-FODMAP diet [27]. Accordingly, the treatment with an antihistamine ebastine also reduced
IBS symptoms in a placebo-controlled trial [28]. Summing up, it might be valuable to determine if
a dysfunctional histamine metabolism in relation to the diet plays a role in IBS and other functional
gastrointestinal disorders.
Our study has several strengths; it was a double-blind, crossover intervention trial, which is
rather rarely possible in the realm of dietary studies [29]. We used a validated symptom measurement,
IBS-SSS, and adherence to the study products was excellent. Study subjects also recorded daily
symptoms at the end of each day; both the IBS-SSS and the daily symptom score showed consistent
improvements in symptoms during the period when they drank the hydrolysed milkshake. The trend of
individual symptoms was also in-line with the total symptoms scores, albeit not statistically significant.
Patients refrained from other dairy products during the interventions, and we also monitored possible
dietary changes but found no differences in macronutrient intakes between the study periods. On the
other hand, a ten-day treatment period may be too short to elicit effects on inflammatory markers,
and the symptom results must be confirmed in longer prospective studies. We used a high protein
dose (50 g/day), and it is uncertain if the results could be attained with a smaller amount of protein.
Interestingly, one previous study detected differences in symptoms between intact and hydrolysed
milk proteins at a dose as low as 7 g/d [11]. Lastly, our study population consisted of IBS, dyspepsia,
diarrhoea and bloating patients, and this mixture of different functional gastrointestinal disorders may
make interpretations of the results more complex.
5. Conclusions
In conclusion, a hydrolysed milk product with a lower casein content reduced gastrointestinal
symptoms in sensitive individuals when compared to an intact milk protein product, but the mechanism
behind the improved tolerance remains to be explained. The modest reduction in symptoms, despite
the high protein dose, implies that casein explains only a small part of the food-related gastrointestinal
symptoms in IBS and FGDs. This was also reflected by the reduction in the overall symptom score
being 19% but less than 50 points in the IBS-SSS.
Nevertheless, lowering the casein content by partial hydrolysation could improve the tolerability
to dairy products in individuals who suffer from FGDs.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/12/7/2140/s1.
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and individual symptom scores during the study periods.
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